









Markets
/
Stocks
/
nasdaq-svra
/

Savara Inc

SVRA

View Detailed Chart

2.666USD

+0.076+2.93%

Market hours （ET）Quotes delayed by 15 min

460.43MMarket Cap

LossP/E TTM



Savara Inc

2.666

+0.076+2.93%

Overview Company Financials

Financials

Intraday

30m

Today

+2.93%

5 Days

+3.33%

1 Month

+21.74%

6 Months

-4.79%

Year to Date

-13.16%

1 Year

-35.91%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 8 analysts

BUY

Current Rating

7.063

Target Price

172.68%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Savara Inc

SVRA

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Ionis Pharmaceuticals Inc

IONS

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(2)

Neutral(3)

Buy(8)

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.055

Buy

RSI(14)

58.249

Neutral

STOCH(KDJ)(9,3,3)

56.967

Neutral

ATR(14)

0.142

Low Volatility

CCI(14)

55.828

Neutral

Williams %R

42.373

Buy

TRIX(12,20)

0.557

Sell

StochRSI(14)

22.181

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

2.604

Buy

MA10

2.534

Buy

MA20

2.436

Buy

MA50

2.350

Buy

MA100

2.651

Buy

MA200

2.892

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Savara Inc. is a clinical-stage biopharmaceutical company, which is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. Molgramostim nebulizer solution is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the molgramostim aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.

Ticker SymbolSVRA

CompanySavara Inc

CEOMr. Matthew (Matt) Pauls, J.D.

Websitehttps://savarapharma.com/